Kangji Medical Holdings Limited

DB:50J Stock Report

Market Cap: €906.8m

Kangji Medical Holdings Valuation

Is 50J undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 50J when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€1.25
Fair Value
42.5% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: 50J (€0.72) is trading below our estimate of fair value (€1.25)

Significantly Below Fair Value: 50J is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 50J?

Key metric: As 50J is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 50J. This is calculated by dividing 50J's market cap by their current earnings.
What is 50J's PE Ratio?
PE Ratio12.8x
EarningsCN¥534.41m
Market CapCN¥6.86b

Price to Earnings Ratio vs Peers

How does 50J's PE Ratio compare to its peers?

The above table shows the PE ratio for 50J vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.1x
PHH2 Paul Hartmann
13.4xn/a€809.8m
EUZ Eckert & Ziegler
28.6x5.2%€1.0b
DRW3 Drägerwerk KGaA
7.9x1.2%€835.9m
RHK RHÖN-KLINIKUM
22.5x7.5%€1.0b
50J Kangji Medical Holdings
12.8x12.1%€7.3b

Price-To-Earnings vs Peers: 50J is good value based on its Price-To-Earnings Ratio (12.8x) compared to the peer average (18.1x).

Price to Earnings Ratio vs Industry

How does 50J's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
50J 12.8xIndustry Avg. 30.7xNo. of Companies9PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 50J is good value based on its Price-To-Earnings Ratio (12.8x) compared to the European Medical Equipment industry average (31.5x).

Price to Earnings Ratio vs Fair Ratio

What is 50J's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

50J PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.8x
Fair PE Ratio21.5x

Price-To-Earnings vs Fair Ratio: 50J is good value based on its Price-To-Earnings Ratio (12.8x) compared to the estimated Fair Price-To-Earnings Ratio (21.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 50J forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.72
€1.04
+43.8%
14.9%€1.19€0.88n/a2
Jan ’26€0.75
€1.04
+38.0%
14.9%€1.19€0.88n/a2
Dec ’25€0.70
€1.04
+47.9%
14.9%€1.19€0.88n/a2
Nov ’25€0.67
€1.01
+51.3%
16.5%€1.17€0.84n/a2
Oct ’25€0.68
€1.01
+48.0%
16.5%€1.17€0.84n/a2
Sep ’25€0.64
€1.01
+57.3%
16.5%€1.17€0.84n/a2
Aug ’25€0.64
€1.14
+80.1%
8.9%€1.25€1.04n/a2
Jul ’25€0.64
€1.18
+86.0%
11.2%€1.31€1.05n/a2
Jun ’25€0.69
€1.18
+69.9%
11.2%€1.31€1.05n/a2
May ’25€0.84
€1.18
+40.9%
11.4%€1.32€1.05n/a2
Apr ’25€0.77
€1.18
+53.7%
11.4%€1.32€1.05n/a2
Mar ’25€0.78
€1.21
+56.6%
14.2%€1.39€1.04n/a2
Feb ’25€0.69
€1.21
+75.9%
14.2%€1.39€1.04n/a2
Jan ’25€0.79
€1.21
+53.5%
13.1%€1.37€1.05€0.752
Dec ’24€0.85
€1.21
+42.6%
13.1%€1.37€1.05€0.702
Nov ’24€0.74
€1.24
+67.1%
14.8%€1.42€1.05€0.672
Oct ’24€0.80
€1.24
+55.5%
14.8%€1.42€1.05€0.682
Sep ’24€0.80
€1.24
+54.6%
16.0%€1.44€1.04€0.642
Aug ’24€0.96
€1.46
+52.1%
13.3%€1.65€1.27€0.642
Jul ’24€0.96
€1.46
+52.1%
13.3%€1.65€1.27€0.642
Jun ’24€1.00
€1.46
+46.0%
13.3%€1.65€1.27€0.692
May ’24€1.14
€1.44
+26.3%
10.9%€1.60€1.28€0.842
Apr ’24€1.09
€1.49
+36.7%
9.5%€1.61€1.29€0.773
Mar ’24€1.13
€1.46
+29.3%
13.4%€1.60€1.18€0.783
Feb ’24€1.10
€1.03
-6.1%
13.7%€1.18€0.89€0.692
Jan ’24€0.95
€1.03
+7.7%
3.3%€1.06€0.99€0.792
Analyst Price Target
Consensus Narrative from 2 Analysts
€1.01
Fair Value
28.7% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 14:45
End of Day Share Price 2025/01/08 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kangji Medical Holdings Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Bo LiCLSA
Chris PanGoldman Sachs